Tag Archives: melbourne

Forecasting the cycle of epileptic seizures

New research throws light on the predictability of seizure cycles for people with epilepsy

 

Cycles govern most aspects of our day-to-day life and our biology.

There are environmental cycles, like the 8-hour working day, 5-day working week, monthly mortgage repayments and seasonal weather patterns.

Epilepsy is particularly sensitive to metabolic cycles. Picture: Shutterstock
There are also cycles in our body governed by hormonal and metabolic activities, like body temperature, sleep and appetite. Longer biological rhythms exist too, like the menstrual cycle, breeding and hibernation.

It is not surprising that so many interwoven cycles can affect human disease in complex ways. Epilepsy is particularly sensitive to metabolic cycles with seizures known to be provoked by poor sleep, heat stress, alcohol consumption, exercise, changes in mood and even the weather.

Breakthrough: Medicinal cannabis and severe epilepsy

Hundreds of years ago, neurologists documented their patients’ seizure times and found reliable patterns that, for some people, were repeated daily, weekly and monthly.

The cause of these cycles was not clear and the cause of longer cycles remained particularly mysterious. For some women, seizures appeared to be linked to menstruation; however, monthly cycles were also common in men.

Baffled, several researchers resorted to supernatural explanations like ‘moon madness’.

FORECASTING CYCLES

Understanding seizure cycles, and being able to forecast when they will occur, has profound implications for better treatment of epilepsy.

We have conducted the largest study of seizure cycles in humans and our research, published in the Lancet Neurology, provides conclusive evidence that multi-day cycles exist for most people with epilepsy.

A major finding from our study is the high rate of seizure cycles in the population which means that cycles could potentially be affecting the treatment of most people with epilepsy.

Seizures can be provoked by poor sleep, heat stress, alcohol consumption, exercise, changes in mood and even the weather. Picture: Getty Images
We still do not understand the causes of seizure cycles and it is difficult to replicate early studies of multi-day seizure cycles because reliable, longitudinal data of individuals’ seizure times is not typically collected.

Early studies were conducted in a world where people travelled less or lived in closed epilepsy colonies where it was much easier to obtain complete records of a person’s seizure times over decades.

MORE THAN JUST A ‘BAD WEEK’

Q&A: How algorithms are fighting epilepsy
Read more

Nowadays, people with epilepsy may report having a ‘bad week’ at the start of each month, a cluster of seizures every 10 days, or other cyclic patterns. However, while anecdotal evidence of long-term seizure cycles is abundant, experimental proof is lacking

Our study was based on two of the largest databases of human seizures ever recorded. The first dataset is from 15 people with epilepsy who were implanted with a device to continuously recorded their brain signals for up to three years.

The second dataset is a non-invasive, online record of peoples’ seizure times reported via a mobile app SeizureTracker.com, with data sharing supported by the International Seizure Diary Consortium.

The implant data provided an extremely accurate, objective account of seizure times since seizures were directly verified from brain activity. App data is based on self-reporting so is more subjective, but reflects a large and diverse cohort of over 10,000 people reporting for up to 10 years.

 

THE SEVEN-DAY CYCLE

We measured the strength of cycles from periods of 12 hours to three months. A majority (86 per cent) of people had at least one significant cycle
Circadian or 24-hour cycles were most common at 83 per cent, however 23 per cent of people had a seven-day cycle. A quarter of the participants also had at least one cycle that was longer than three weeks.

Gathering self-reported data on peoples’ seizures via a mobile app meant researchers could capture a large and diverse dataset. Picture: Pexels
The existence of a precise seven-day cycle in over one fifth of the cohort was staggering. These weekly cycles suggest human brain activity is entrained to an artificial seven-day week in addition to our brain’s well-documented synchrony with the 24-hour light cycle.

The weekday that most seizures occurred was unique to the individual and, across the population, no day of the week was ‘worse’ than any other day. Like many researchers before us, we also found that longer cycles were equally common in men and women.

So what are the implications of our findings?

 

TREATMENT IMPLICATIONS

Failing to account for multi-day cycles could lead to inconsistent treatment decisions.

For instance, if medication changes were made at the high point of someone’s cycle there would be a perceived benefit because afterwards seizures would begin to decrease.

After the low point of the cycle however, seizures would begin to increase and the drug would seem to be performing badly. Similarly, tracking seizure cycles during clinical trials is important to properly measure the effectiveness of a new drug.

Perhaps the most exciting aspect of this research is that cycles were measured from self-reported mobile seizure diaries. By developing the right software, we can immediately begin using the information from seizure cycles to improve treatment outcomes.

A SEIZURE FORECASTING APP
The main aim of my research is to develop a seizure forecasting app and this study is an important step towards that goal. At our start-up company, Seer, we have developed Beagle Health Tracker, an app that detects the different cycles that modulate individuals’ seizures and present this information graphically.

The Beagle Health Tracker app helps users plan according to their how likely they are to have a seizure that day.

Users can track where they are in a particular cycle, explore the different associated risk levels and schedule medication to align to their unique rhythms. The next step is to incorporate additional data to build a more nuanced picture of an individual’s seizure likelihood.

One important data source available soon is brain signals recorded from outside the skull. Recently our team, lead by Professor Mark Cook, announced that a trial of Minder, a sub-scalp implant device, will begin in Melbourne as early as next year. Devices like Minder are anticipated to revolutionise seizure forecasting.

However, it is important to begin the data collection process now.

Our investigation has taught us that tracking seizure times can reveal rich patterns that can be used to build better forecasts and make a real difference to how people manage epilepsy.

 

This article is sourced from our Proud Precinct Partner,  the University of Melbourne

 

Download the Beagle Health Tracker app

Thinking of studying Biomedicine? – 12 Dec

photo of students in lab coats and safety glasses examining a fragment of skull.

Thinking about studying Biomed with the University of Melbourne in 2019?

Join us on Facebook Live as we talk to a panel of Biomed students and academics about everything you need to know for 2019.

This is your opportunity to chat with students and recent graduates about what it’s really like to study Biomed, careers, scholarships, internships, exchange and much, much more!

 

Hear from the The University of Melbourne’s Dean of the Faculty of Medicine, Dentistry and Health Sciences.

 

 

More information about the University of Melbourne

Established in 1853, The University of Melbourne is a public-spirited institution that makes distinctive contributions to society in research, learning and teaching and engagement. We are
committed to being one of the finest universities in the world, contributing to society in ways that enrich and transform people’s lives. Ranked as the number 1 University in Australia and
32 in the worldQ, The University of Melbourne offers a uniquely Australian experience helping graduates become well-rounded, thoughtful and skilled professionals capable of making a
positive and global impact. Situated in the heart of Australia’s second largest city, Melbourne has a fast-growing population of approximately four million. It is an international cultural
hub characterised by friendly people, festivals, sporting events, architecture, art, cuisine, an outdoor lifestyle, green spaces and beaches.

More about the Melbourne Biomedical Precinct

Melbourne has biomedical capabilities unparalleled in Australia and the Melbourne Biomedical Precinct ranks as one of the best facilities of its kind in the world. Located on the edge of the CBD, the precinct is a hub of innovation, home to an exceptional network of skilled workers, quality education providers and leading research institutes and hospitals.

 

This article is sourced from the University of Melbourne Medicine, Dentistry & Health Sciences Facebook page and the Faculty Brochure.

University of Melbourne are Proud Precinct Partners.

Special evening lecture: Professor Wim H. van Harten – 29 November

Wide angle shot of the VCCC, a christmas tree is on the ground floor.

Value Transformation in Dutch Hospitals: Portfolios, Pathways and New Models of Care

Visiting Professor Wim H. van Harten will present a special evening lecture during his visit to Australia.  Wim H. van Harten is the CEO of Rijnstate (general) Hospital in Arnhem, a large teaching hospital with an annual expenditure of € 460 million and around 4500 employees, of whom around 275 are medical specialists and 130 MDs in specialist training.

The presentation will provide insights on the concentration of health services from a European perspective, along with networks in oncology and the development of hospitals taking responsibility for delivery of specialised care at home.

Professor Wim H. van Harten MD, PhD, MPH

Wim H. van Harten spent 5 years in Cameroon after his graduation as M.D. and specialisation in tropical medicine. On returning from Africa he focused on public health and health administration. He obtained a degree in community medicine/public health while working as Chief Medical Advisor of a major health insurance company (1986-1992). He completed his PhD on quality management in health care (1997) and started a research group in close cooperation with the University of Twente.

In June 2001, he became Member of the Executive Board of the Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital (NKI-AVL), a prominent European Comprehensive Cancer Center in Amsterdam, The Netherlands, being in charge of Organisation & Management. The NKI is the only designated Comprehensive Cancer center in the Netherlands with an annual expenditure of over € 300 million. From 2005 he was acting as Research Group leader at the Division of Psychosocial Research and Epidemiology at the NKI.

Since 2001 he is part-time professor on Quality Management and Health Care Technology at the department of Health Technology and Services Research of the School of Management and Governance at the University of Twente, the Netherlands. After serving on the board of the Organization of European Cancer Institutes (OECI) for a number of years, he served as President of the OECI from 2011-2014. He is a member of the Accreditation and Designation Group of the OECI. He is one of the founders of this system and chaired reviews of major centers like Cambridge, Manchester/Christies, Helsinki University and Oslo University. He chairs the OECI working group on health economics.

From 2008 – 2014 he was chosen to serve as Board member of the Netherlands Hospital Association with the portfolio of innovation, drug costs and quality issues.

In December 2015 he started as CEO of Rijnstate (general) Hospital in Arnhem. In the annual insurers survey on 2015, Rijnstate ranked fourth in annual patient volume in the Netherlands. Presently a large 10-year renovation investment plan is underway involving total restructuring real estate and facilities, innovating clinical in-patient services, upgrading R&D structure and heavy IT, EMR and data mining investments. Rijnstate serves as a business school ‘care study’ of IESE/Barcelona in its 2018 curriculum in The Hospital of the Future.

Details for the Evening Lecture:

Date: Thursday 29 November 2018
Venue:  VCCC Building, Level 7 Lecture Theatres
Time: Presentation: 5-6pm

Followed by networking refreshments in the foyer
Register here

MTGT Pre-Accelerator Week – 10-14 December

Branding image for the Medtech's got talent Pre-accelerator program, 10 to 14 December 2018

If you have an interest in learning more about MedTech commercialisation, you can attend this one week course delivered by prominent experts in the Australian medical devices industry.

The course content is listed below:

December 10, 2018, 12.45 – 5.00pm | Regulatory, reimbursement and clinical trials pathway
December 11, 2018, 8.30am – 3.30pm | Intellectual property and business law
December 12, 2018, 8.30am – 3.00pm | Product development, design thinking and commercialisation trajectory
December 13, 2018, 8.30am – 3.30pm | Capital raising, financing MedTech innovation and exit strategies
December 14, 2018, 8.30 – 12.45pm | Social media and market research for emerging MedTech start-ups
Tickets can be purchased for either half-day/full-day workshops or the full five days sessions.

Prices range from $80 per day to $200 for all sessions.

 

DATE AND TIME
Mon., 10/12/2018, 8:00 am –
Fri., 14/12/2018, 12:45 pm AEDT

LOCATION
Goods Shed North
710 Collins Street
Docklands, VIC 3008

 

Australia’s First National Medtech Accelerator!

We set a new global standard for medical technology commercialisation acceleration. Our program deploys a dynamic, integrated program that supports rapid transformation of new ideas into solutions that change the face of global healthcare.

MedTech startups accelerate from Seed stage to Series A in 15 months by combining talented creativity with disruptive financial models and comprehensive domain expertise, and by supporting leadership development to create the next generation of advanced technology entrepreneurs.

Milestone momentum is rewarded with multiple capital injection points and the program is tightly linked to startup pathways across the globe. Driven by industry leadership, investor connectivity and market pull mechanisms, The Actuator is in the business of signal not noise: focusing on what really matters to transform healthcare and the future of innovation.

The Actuator is also home to MedTech’s Got Talent – www.medtechchallenge.com

You can download more information about the Melbourne Biomedical Precinct Medical Devices can be found here

Restoring sight: Australia’s bionic eye

Bionic eye glasses and headgear displayed on a mannequin with the receiver attached.

Four patients have had a sense of vision restored after having Australia’s bionic eye surgically implanted as part of a clinical trial in Melbourne, Victoria.

The four patients have a degenerative genetic condition called Retinitis Pigmentosa which causes loss of vision. It affects about one in every 4,000 people, affecting 1.5 million people worldwide. It is the leading cause of inherited blindness; there is currently no cure.

In 2012, three patients were implanted with an early version of the device which showed success, but restricted use to the lab.
This second-generation device allows patients navigate outside and, more importantly, in their homes without the need for supervision. Melbourne researchers have been working hard to create the portable and permanent device over the last five years, to ensure that patients with the implant can have an improved quality of life.

The bionic eye consists of both implanted and body worn components. The patient wears glasses with a small video camera mounted on the side. Then, the live feed from the camera is processed and transmitted via an implanted microchip to an electrode array placed in a naturally occurring pocket behind the retina, called the suprachoroidal space. The electrodes stimulate remaining cells in the retina, to generate spots of light that give a patient a sense of vision.

Associate Professor Penny Allen, head of the Vitreoretinal Unit at The Royal Victorian Eye and Ear Hospital, said she was pleased with the results.

“Each of the patients has returned home after surgery and are working with the clinical and research team to learn to use the device and incorporate it into their everyday lives.

“Based on our results so far, we know that our approach is safer and less invasive, and the patients have all made impressive progress with mobility and activities of daily living,” said A/Prof Allen.

Article sourced from The Bionics Institute, a proud  Melbourne Biomedical Precinct Partner